

CURRICULUM VITAE

Professor Clive Loveday MBBS.FIBiol.CBiol.MFSEM(UK).PhD.FRCPath.

Degrees (Subject, class, university, date)

- HND - Applied Biology (Microbiology/Pharmacology) University East London, 1967
- MIBiol. – Microbiology/Pharmacology, I/II, University East London, 1969
- PhD – Dynamics of Inflammation, University of London, 1974
- MBBS – Degree in Medicine, Middlesex Hospital, University of London, 1980
- JCPTGP – Higher professional training PHC, Norwich University Hospital, 1984
- MRCPPath – Higher professional training (Virology), University of London, 1993
- FRCPath – Elevation to fellow of College for academic and clinical service, 2001
- FIBiol. – Elevation to fellow of the Institute for academic and scientific service, 2009

Posts held with dates commencing with current posts

- Clinical Director of International Clinical Virology Centre (ICVC) Charitable Trust – Academic and clinical research laboratories 2002 – onwards
- Clinical Consultant in GUM/HIV, South Buckinghamshire NHS Trust –2002 – onwards
- Honorary Consultant Barts and Royal London NHS Trust (HIV care) -2004 – onwards
- Consultant Lead in Community-based GUM/HIV service in Bucks. -2007 – onwards
- Honorary Professor in Department of Sexual Health, Thames Valley University (London) – 2004 – onwards
- Member of MRC College of Experts and Senior Staff. 2002-onwards

- Foundation Professor of HIV/AIDS and Clinical Consultant and Head of Department, Royal Free and University College Hospital and Medical School, 1996 – 2002
- Clinical Consultant/Senior Lecturer in Virology, University College London, 1994-1996
- Senior Registrar in Clinical Virology, University College, London, 1991-1994
- HIV Molecular Research Leader, University College, London, 1988 – 1996
- Lecturer in Clinical Virology (District AIDS Officer), University College London Medical School (organizer of HIV/AIDS services) 1988-1994
- 'New Blood' Lecturer in HIV/AIDS, Academic Department of GUM/HIV, Middlesex Hospital Medical School, 1985-1988
- Training posts (intern and resident) in general medicine and primary health care 1980-85

Academic Honours

- Honorary Professor of Thames Valley University for Lifetime Contributions to HIV/AIDS Health Care and Health Care Education (2004)

Significant Grants Awarded for HIV Trials

- MRC/ANRS CONCORDE TRIAL – UK trial virologist – 1988-1991
- MRC/ANRS/Dutch DELTA TRIAL – UK trial virologist – 1990-1995
- MRC QUATTRO TRIAL – Trial virologist – 1992-1995
- MRC AWARD –Changes in VL/Resistance and Clinical Outcomes – 1999-2001
- MRC ESPRIT TRIAL – UK clinical Virologist – 2000-2003
- MRC AWARD – Epidemiology and Clinical Virology of HIV NB Infections.- 2000-2003
- MRC FORTE TRIAL – Trial virologist – 1996 – 2004
- MRC ERA TRIAL – Trial Principal Investigator and virologist – 2000-2005
- MRC/ANRS/NCHE INITIO TRIAL – Virology Co-Chair with F.Brunvezinet, 2000-2008
- EU 5th FRAMEWORK AWARD – Virological Support for EuroSIDA - Partner, Virology Chair – 2001-2005

Contributions to Clinical Service and Scientific Advancement in HIV/AIDS

Professor Loveday started working as a young clinician and scientist in this field when HIV-1 antibody assay first became available in the UK. He was part of an MRC HIV Natural History Study grant at the Middlesex Hospital. He cared for a cohort of new HIV-positive patients, and contributed to a series of clinical studies to understand the pathogenesis of HIV and ran a series of sero-prevalence studies to understand the spread of HIV in the community in UK. He was the clinician running the Middlesex Hospital limb of the first UK AZT trial. In 1988 he transferred to clinical virology to head up a team applying the new PCR technology to the study of HIV. By 1988 the team established a diagnostic PCR assay for the hospital and blood transfusion service, and the first quantitative viral load (1990) and resistance assay (1991) in the world to support patient care. Using these assays his group were the first to demonstrate the rapid dynamics of HIV replication (1994). During this time he contributed to international HIV clinical trials and undertook a higher professional training as a clinical virologist. In 1996 he became the Professor and Head of Department of the first UK HIV/AIDS department to establish a molecular virology service. In 1997 he identified the molecular diversity of NB subtypes and the loss of signal in the Roche viral load assay; he contributed to the revision of this assay and wrote the FDA submission for version 1.5. During this time he contributed to MRC and EuroSIDA trials. In 2002, with the support of the Royal Free Hospital he devolved the clinical and research activities to the ICVC Charitable Trust. This made the best use of \$4 million dollars of financial support from MRC, EU and industrial sources to give optimum clinical care for patients outside the constraints and turmoil of a shrinking NHS and hospital services in central London.

Significant Publications

- Carne CA, Weller IVD, **Loveday C** et al. Prevalence of antibodies to human immunodeficiency virus, gonorrhoea rates and changes in sexual behaviour in homosexual men in London. **Lancet** 1987; i:656-659
- **Loveday C**, Pomeroy L, Weller IVD et al. Human immunodeficiency viruses in patients attending a sexually transmitted disease clinic in London. **Br.Med.J.** 1989; 298:419-423
- Semple MG, **Loveday C**, Tedder RS et al. Direct measurement of viraemia in patients infected with HIV-1 and its relationship to progression and zidovudine therapy. **J Med. Virol.** 1991; 35:38-45
- Kaye S, **Loveday C**, Tedder RS. A microtitre format point mutation assay: application in detection of drug resistance in HIV-1 infected patients treated with zidovudine. **J Med Virol.** 1992; 37: 241-246
- **Loveday C**. An approach to quantification and dynamics of serum HIV-1 RNA by PCR. Ann. Scientific Meeting Clinical Pathologists. Oct 20-21st 1994. In: Haeney MR ed. The Ass. Of Clin Virol. Yearbook 1995, London: 70-73.
- **Loveday C**, Kaye S, Tennant Flowers M et al. HIV-1 RNA serum load and resistance genotypes during early HIV therapy. **Lancet** 1995; 345:820-824
- Katlama C, Ingrand D, **Loveday C** et al. The 3TC EU working Group: Safety and efficacy of 3TC/AZT combination therapy in drug naïve patients. **JAMA** 1996; 276: 118-125
- Devereux H, Youle M, Johnson M, **Loveday C**. Rapid decline in detectable HIV-1 drug resistant mutations when therapy is stopped. **AIDS** 1999; 13: F123-128
- Hirsch M, Brun-Vezinet F, D'Aquila R, Hammer S, Johnson V, Kuritzkes D, **Loveday C**, Mellor J, Clotet B, Conway B, Demeter L, Jacobsen D, Richman D. Antiretroviral drug resistance: testing in adult HIV infection. **JAMA** 2000; 283:2417-2426
- **PENTA** committee. The impact of HIV-1 subtypes on virological response and emergence of resistance in PENTA 5 trial. **AIDS** 2003
- Cambra C, Cozzi Lepri A, **Loveday C** et al EuroSIDA. Baseline resistance and virological outcome in patients who start NNRTI regimen. **Antiviral Ther.** 2004 9:787-800
- **ERA** MRC Clinical trials investigators. A randomised controlled trial of the value of phenotypic drug resistance in addition to genotypic testing for HIV resistance. **J Acq.Immune Defic.Syindr.** 2005, 38:553-559
- Bannister WP, Ruiz L, **Loveday C** et al EuroSIDA. HIV-1 subtype and response to combination ART therapy in Europe. **Antiviral Ther.** 2006, 11:707-715